Exosome microRNA signatures in patients with complex regional pain syndrome undergoing plasma exchange.
3' Untranslated Regions
/ genetics
Adult
Base Sequence
Complex Regional Pain Syndromes
/ blood
Exosomes
/ genetics
Female
Gene Expression Regulation
HEK293 Cells
Humans
Interleukin-6
/ blood
Male
MicroRNAs
/ genetics
Middle Aged
Plasma Exchange
RNA, Messenger
/ genetics
THP-1 Cells
Tumor Necrosis Factor-alpha
/ blood
Biomarker
Exosomes
Inflammation
Plasma exchange
miRNA
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
14 03 2019
14 03 2019
Historique:
received:
31
10
2018
accepted:
06
03
2019
entrez:
16
3
2019
pubmed:
16
3
2019
medline:
24
4
2020
Statut:
epublish
Résumé
Therapeutic plasma exchange (PE) or plasmapheresis is an extracorporeal procedure employed to treat immunological disorders. Exosomes, nanosized vesicles of endosomal origin, mediate intercellular communication by transferring cargo proteins and nucleic acids and regulate many pathophysiological processes. Exosomal miRNAs are potential biomarkers due to their stability and dysregulation in diseases including complex regional pain syndrome (CRPS), a chronic pain disorder with persistent inflammation. A previous study showed that a subset of CRPS patients responded to PE. As a proof-of-concept, we investigated the PE-induced exosomal miRNA changes in six CRPS patients. Plasma cytokine levels were measured by HPLC and correlated with miRNA expression. Luciferase assay following co-transfection of HEK293 cells with target 3'UTR constructs and miRNA mimics was used to evaluate miRNA mediated gene regulation of target mRNA. Transient transfection of THP-1 cells with miRNA mimics followed by estimation of target gene and protein expression was used to validate the findings. Comparison of miRNAs in exosomes from the serum of three responders and three poor-responders showed that 17 miRNAs differed significantly before and after therapy. Of these, poor responders had lower exosomal hsa-miR-338-5p. We show that miR-338-5p can bind to the interleukin 6 (IL-6) 3' untranslated region and can regulate IL-6 mRNA and protein levels in vitro. PE resulted in a significant reduction of IL-6 in CRPS patients. We propose that lower pretreatment levels of miR-338-5p in poor responders are linked to IL-6 levels and inflammation in CRPS. Our data suggests the feasibility of exploring exosomal miRNAs as a strategy in patient stratification for maximizing therapeutic outcome of PE.
Sections du résumé
BACKGROUND
Therapeutic plasma exchange (PE) or plasmapheresis is an extracorporeal procedure employed to treat immunological disorders. Exosomes, nanosized vesicles of endosomal origin, mediate intercellular communication by transferring cargo proteins and nucleic acids and regulate many pathophysiological processes. Exosomal miRNAs are potential biomarkers due to their stability and dysregulation in diseases including complex regional pain syndrome (CRPS), a chronic pain disorder with persistent inflammation. A previous study showed that a subset of CRPS patients responded to PE.
METHODS
As a proof-of-concept, we investigated the PE-induced exosomal miRNA changes in six CRPS patients. Plasma cytokine levels were measured by HPLC and correlated with miRNA expression. Luciferase assay following co-transfection of HEK293 cells with target 3'UTR constructs and miRNA mimics was used to evaluate miRNA mediated gene regulation of target mRNA. Transient transfection of THP-1 cells with miRNA mimics followed by estimation of target gene and protein expression was used to validate the findings.
RESULTS
Comparison of miRNAs in exosomes from the serum of three responders and three poor-responders showed that 17 miRNAs differed significantly before and after therapy. Of these, poor responders had lower exosomal hsa-miR-338-5p. We show that miR-338-5p can bind to the interleukin 6 (IL-6) 3' untranslated region and can regulate IL-6 mRNA and protein levels in vitro. PE resulted in a significant reduction of IL-6 in CRPS patients.
CONCLUSIONS
We propose that lower pretreatment levels of miR-338-5p in poor responders are linked to IL-6 levels and inflammation in CRPS. Our data suggests the feasibility of exploring exosomal miRNAs as a strategy in patient stratification for maximizing therapeutic outcome of PE.
Identifiants
pubmed: 30871575
doi: 10.1186/s12967-019-1833-3
pii: 10.1186/s12967-019-1833-3
pmc: PMC6419338
doi:
Substances chimiques
3' Untranslated Regions
0
Interleukin-6
0
MicroRNAs
0
RNA, Messenger
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
81Subventions
Organisme : NINDS NIH HHS
ID : R01 NS102836
Pays : United States
Références
Genome Biol. 2017 May 5;18(1):83
pubmed: 28476144
Nucleic Acids Res. 2018 Jan 4;46(D1):D239-D245
pubmed: 29156006
Nucleic Acids Res. 2015 Jan;43(Database issue):D146-52
pubmed: 25378301
Pain. 2014 Aug;155(8):1527-39
pubmed: 24792623
J Transl Med. 2011 Nov 10;9:195
pubmed: 22074333
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Pain. 2011 Dec;152(12):2690-700
pubmed: 21816540
Pain Med. 2014 Dec;15(12):2163-4
pubmed: 25352061
Ther Apher Dial. 2016 Aug;20(4):348-53
pubmed: 27523074
Pain. 2015 Apr;156 Suppl 1:S94-103
pubmed: 25789441
Eur J Pain. 2015 Apr;19(4):503-7
pubmed: 25115658
Transplantation. 2013 Apr 27;95(8):1021-9
pubmed: 23591727
BMJ. 2015 Jul 29;351:h2730
pubmed: 26224572
Noncoding RNA. 2017 Feb 23;3(1):
pubmed: 29657282
Am J Kidney Dis. 2008 Dec;52(6):1180-96
pubmed: 18562061
J Clin Apher. 2016 Aug;31(4):368-74
pubmed: 26011726
J Extracell Vesicles. 2014 Dec 22;3:26913
pubmed: 25536934
Pain Physician. 2015 Jul-Aug;18(4):383-94
pubmed: 26218942
Clin Biochem. 2013 Jul;46(10-11):846-60
pubmed: 23562576
Nat Methods. 2017 Feb 28;14(3):228-232
pubmed: 28245209
Cell Death Differ. 2015 Jan;22(1):22-33
pubmed: 25190144
J Transl Med. 2016 Mar 03;14:64
pubmed: 26940669
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Neurology. 2013 Jan 1;80(1):106-17
pubmed: 23267031
Trends Mol Med. 2017 Jul;23(7):636-650
pubmed: 28648185
J Pain. 2015 Sep;16(9):814-24
pubmed: 26072390
J Clin Invest. 2016 Apr 1;126(4):1139-43
pubmed: 27035805
J Immunol. 2012 Jan 1;188(1):454-61
pubmed: 22105995
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):94-7
pubmed: 23154126
Trials. 2014 Oct 24;15:404
pubmed: 25344328
Nat Commun. 2011;2:282
pubmed: 21505438
Ther Apher Dial. 2017 Feb;21(1):6-21
pubmed: 28078733
Elife. 2015 Aug 12;4:
pubmed: 26267216